About Mironid
Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease. Its lead programme is for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which is characterized by uncontrolled growth of fluid-filled cysts and is the most common hereditary kidney disorder, but has limited treatment options. Mironid’s first-in-class small molecule LoAc® drug candidates directly target the abnormally high kidney cAMP levels that drive cyst formation. The Company is led by an industry-experienced management team and supported by a strong advisory network and blue-chip investors including Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures. The University of Strathclyde, Scottish Investment Bank and the European Investment Fund (EIF) are also investors in Mironid.
Why we invested
The investment aligns strongly with the Bank’s Innovation mission, supporting the development of products and services that improve human wellbeing.
“We are pleased to join a committed group of investors to support the company through this critical stage of development, helping it translate world-class research into clinical progress, commercial opportunity and potential patient benefit.”
Key Information
Key Quote
Neil Wilkie, CEO of Mironid said: “ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. Securing funding from such a high-caliber syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases.”
Alignment to the United Nation's Sustainable Development Goals
Good Health and Well-being
